Request a consultation

Botulinum toxin in the UK: who can prescribe it, who can administer it, and why you never see it advertised

november 2026

Please read first: This guide is general information about a prescription-only medicine and the law surrounding it. It is not an advertisement, it contains no pricing information and is not a substitute for individual medical advice.

Botulinum toxin is a prescription-only medicine. It was developed to treat neurological conditions of the eye and face, and its use in cosmetic treatment was discovered by accident some fifteen years later. In the UK, its prescription is tightly controlled, its administration is not, and advertising it to the public is unlawful.

Those rules are poorly understood by patients, in part because the advertising restrictions make them difficult to set out anywhere a patient would think to look. This guide covers what the medicine is, where it came from, and the law as it currently stands.

Top Tip: The person who prescribed the medicine is clinically responsible for the decision to give it to you, and they should have assessed you in person before doing so. Ask whether the person who assessed you face to face is the same person who prescribed it, then check their name on the relevant register.

Medically reviewed by Dr Munroe

key takeaways.

  • Botulinum toxin is a prescription-only medicine, which is why UK clinics cannot advertise it by name, by brand, or by any of the euphemisms that have grown up around it.
  • It should only be prescribed by someone who has assessed you in person. Prescribing from a photograph, a form, or a list of names supplied by whoever will be injecting does not meet professional standards.
  • Only an independent prescriber may prescribe it. Doctors and dentists can do so as part of their primary qualification; nurses, pharmacists and certain allied health professionals must complete a further qualification to prescribe at all.
  • In England, the law does not currently restrict who may administer it once it has been prescribed. That is a separate question from who may prescribe it, and the distinction surprises most people.
  • Several different products hold UK licences. They are not interchangeable, and their dosing units do not convert between brands.

1. What it actually is

Botulinum toxin is a protein produced by a bacterium called Clostridium botulinum. The name comes from botulus, the Latin for sausage, because the illness it causes was first identified in people who had eaten spoiled preserved meat.

It works by blocking the release of acetylcholine, the chemical messenger a nerve uses to tell a muscle to contract. The nerve still fires, but the message doesn't arrive, so the muscle stays relaxed. The effect is temporary: the nerve endings recover over a period of months and normal function returns.

The doses used medically are very small, and the product is purified and standardised to a measured strength. It is a manufactured medicine rather than the toxin as it occurs in contaminated food.

It also acts locally. Once injected into a muscle, it affects the nerve endings within a short radius of where it was placed rather than circulating around the body. That is why the placement and the dose matter so much, and why the same medicine can be used in areas as different as the forehead and the bladder without one affecting the other.

2. From poison to medicine

The cosmetic use came last, and it came by accident.

In the 1820s a German physician called Justinus Kerner investigated a series of deaths from spoiled sausage, described the syndrome in detail, and suggested that the poison responsible might one day be useful as a treatment if given in tiny enough doses. He was about 150 years early. The organism itself was isolated in the 1890s after an outbreak in Belgium.

In the 1970s Alan Scott, an ophthalmologist working in the United States, developed it as an alternative to surgery for squint. The first approvals followed in the late 1980s, for squint, blepharospasm (involuntary forceful blinking) and related conditions of the eye and face.

In the early 1990s two Canadian clinicians, Jean and Alastair Carruthers, noticed that patients being treated for blepharospasm kept mentioning that their frown lines had softened. They investigated it and published. That observation, made in patients being treated for something else entirely, is where the cosmetic use begins.

It is now licensed or used for a wide range of conditions, including chronic migraine, overactive bladder, excessive sweating, muscle spasticity after stroke, voice disorders and facial palsy.

3. The names on the box

Botulinum toxin type A is the medicine. The names people use are brands, and each brand is a separate product with its own licence.

The best-known of those names has a history of its own. Alan Scott's original formulation was licensed under the name Oculinum, meaning "eye aligner", for the treatment of squint and blepharospasm. Allergan acquired it at the start of the 1990s and renamed it Botox.

Some products are licensed for cosmetic use, some only for therapeutic use, and the same manufacturer may hold both under different names. Dysport and Azzalure are one such pair; Xeomin and Bocouture are another. Same molecule, different name, different licensed purpose.

Seven products currently hold UK licences for cosmetic use:

ProductManufacturer / UK distributor
Botox®Allergan / AbbVie
Azzalure®Ipsen / Galderma
Bocouture®Merz Aesthetics
Nuceiva®Evolus / Altius Healthcare
Letybo®Hugel / Croma-Pharma
Alluzience®Ipsen / Galderma
Relfydess®Galderma

Alluzience and Relfydess are supplied as ready-to-use liquids rather than powders requiring reconstitution, Alluzience being the first of these; Relfydess uses a different active substance, relabotulinumtoxinA. Products differ in formulation, in how quickly they take effect and in how long that effect lasts, which is among the reasons a prescriber may select one over another.

Doses are measured in units, and a treatment is usually described by the number of units placed in a given area. Each manufacturer defines its own unit using its own potency testing, so a unit is specific to a single product. Twenty units of one product is not the same amount of medicine as twenty units of another.

This matters most when comparing clinics. A number quoted by one clinic tells you very little unless you also know which product it refers to, so if you are given a number, ask which product it applies to.

As for why you so rarely see any of these names written down: that is the advertising rules at work, not clinics being coy. More on that below.

4. Who can prescribe it

Only an independent prescriber can prescribe botulinum toxin, and not every healthcare professional is one.

Doctors and dentists can prescribe as part of their primary qualification. Nurses, pharmacists and certain allied health professionals cannot. Registration with the Nursing and Midwifery Council, the General Pharmaceutical Council or the Health and Care Professions Council does not, by itself, confer any right to prescribe.

To prescribe independently, they must complete a separate accredited prescribing programme after qualifying. That means university-based study, a period of supervised practice overseen by a designated prescribing practitioner, written examinations, a numeracy assessment and a portfolio of assessed practice. It is a substantial additional qualification, not an afternoon's training.

Once completed, it is recorded as an annotation on that person's entry in their professional register. This is the useful part for patients: you can check whether the person prescribing for you is actually qualified to prescribe, not simply qualified. The registers are listed in the next section and all are free to search.

The other requirement is that the prescriber must assess you in person. A prescription is written for a named patient, following an assessment of that patient. Prescribing from a photograph or an online form does not meet professional standards, and nor does prescribing against a list of names supplied by whoever is going to do the injecting. Pre-signed or blank prescriptions fall the same way.

The assessment is the clinical part of the process. It is where your medical history, your current medication, any previous reactions and any contraindications are established, and it is how your suitability for treatment is decided. An appointment that goes straight to injecting has skipped it.

This has a practical consequence for how an appointment is structured.

If the person injecting you is also the prescriber, they can assess you and treat you at the same visit. If they are not, the medicine has to be prescribed for you by name, dispensed against that prescription by a pharmacy, and delivered to the clinic before anyone can administer it. That sequence takes time. Either the prescriber attends and assesses you in person on the day, or there is a gap of several days between your assessment and your treatment.

What should not happen is a non-prescriber assessing you and then injecting from a supply already held at the clinic. Medicine kept as general stock has not been prescribed for you, and no prescriber has made a decision about whether it is appropriate for you.

If you are booked for a consultation and treatment in a single appointment, it is reasonable to ask who will be prescribing, whether they will be present, and when the medicine was prescribed.

These standards are set and enforced by the professional regulators, and the consequence for a prescriber who ignores them is their registration.

5. Who can administer it

This is where most people's assumptions come apart. In England there is currently no law restricting who may administer a prescription-only medicine to the person it was lawfully prescribed for. The injection itself is not the regulated act.

What is regulated is the decision to prescribe, and the prescriber remains clinically responsible for that decision. So the questions worth asking are who assessed you, whether they did it in person, and which professional regulator they are registered with.

The professional registers, and who each covers:

RegisterCovers
General Medical Council (GMC)Doctors
General Dental Council (GDC)Dentists and dental care professionals
Nursing and Midwifery Council (NMC)Nurses and midwives
General Pharmaceutical Council (GPhC)Pharmacists
Health and Care Professions Council (HCPC)Physiotherapists, podiatrists, paramedics and other allied health professionals

All are searchable by name, free, and take about a minute.

An independent prescriber may only prescribe within their own area of competence, which is why you will rarely see a prescriber from outside medicine, dentistry, nursing and pharmacy in this setting.

There are also voluntary registers for practitioners and clinics, run by the Joint Council for Cosmetic Practitioners and by Save Face. Voluntary is the operative word: they are a useful signal, not a legal requirement, and absence from them is not in itself a red flag.

What about the licensing scheme everyone talks about? Section 180 of the Health and Care Act 2022 gives the Secretary of State the power to create one, covering both individual practitioners, through a personal licence, and the premises they work from, through a premises licence. The procedures it would cover explicitly include injecting substances such as botulinum toxin.

That section came into force in July 2022. But it is an enabling power: it permits a scheme rather than creating one, and the secondary legislation that would actually switch it on has still not been made. No commencement date has been set, and in September 2026 MPs warned that the continuing delay is leaving patients exposed.

So at present there is no personal licence and no premises licence in existence, nothing to apply for, and nothing for a patient to check. Parliament legislated for this four years ago and it has not yet been turned on.

One area is already law. Administering botulinum toxin for cosmetic purposes to anyone under 18 in England has been a criminal offence only since October 2021, which is considerably more recent than most people assume.

6. Why you never see it advertised

Botulinum toxin is a prescription-only medicine, and prescription-only medicines cannot be advertised to the public in the UK.

That applies to social media as much as to formal advertising, which is why clinics refer to it indirectly, or not at all, and why the language around it has become so oblique.

If this information is hard to find, that is the law working as intended. It exists so that the decision to take a prescription medicine is reached through clinical assessment rather than through marketing.

common questions.

Why can't clinics advertise Botox in the UK?

Because it is a prescription-only medicine, and prescription-only medicines cannot be advertised to the public. The restriction covers social media as well as conventional advertising, which is why clinics tend to refer to it indirectly or not at all.

Is Botox the same as botulinum toxin?

Not quite. Botulinum toxin type A is the medicine; Botox is one brand of it. Several other brands hold UK licences, each a separate product, and their dosing units do not convert between brands.

Who can legally prescribe botulinum toxin in the UK?

Only an independent prescriber. Doctors and dentists can prescribe as part of their primary qualification. Nurses, pharmacists and certain allied health professionals must complete a further accredited prescribing qualification, which is recorded on their professional register and can be checked.

Can a beautician inject botulinum toxin?

In England there is currently no law restricting who may administer it once it has been lawfully prescribed for a named patient. What is regulated is the prescribing: the prescriber must be an independent prescriber, must have assessed you in person, and remains clinically responsible for that decision.

What was botulinum toxin originally used for?

Eye and neurological conditions. It was developed in the 1970s as an alternative to surgery for squint, and first approved in the late 1980s for squint and blepharospasm. The cosmetic use was noticed by accident in patients being treated for blepharospasm in the early 1990s.

What is R-CPD, or the inability to burp?

R-CPD, sometimes called no-burp syndrome, is an inability to belch caused by a muscle at the top of the oesophagus failing to relax. Symptoms include gurgling in the throat, bloating, excessive flatulence and chest discomfort after eating or drinking, and are typically worse with fizzy drinks and beer. It is treated by injecting botulinum toxin into that muscle, usually by an ENT specialist. This is not a treatment offered at this clinic; the route is a GP or ENT referral.

references.

  1. MHRA. Products database, for licensed botulinum toxin products and their indications. https://products.mhra.gov.uk
  2. Health and Care Act 2022, section 180 and Schedule 19. https://www.legislation.gov.uk/ukpga/2022/31/contents/enacted
  3. Department of Health and Social Care. The licensing of non-surgical cosmetic procedures in England: consultation response, August 2025. https://www.gov.uk/government/consultations/licensing-of-non-surgical-cosmetic-procedures/outcome/the-licensing-of-non-surgical-cosmetic-procedures-in-england-consultation-response
  4. Hamilton Fraser. Government delays on high-risk cosmetic procedures are putting patients at risk, MPs warn, September 2026. https://www.hamiltonfraser.co.uk/content-hub/government-delays-on-high-risk-cosmetic-procedures-are-putting-patients-at-risk-mps-warn
  5. Botulinum Toxin and Cosmetic Fillers (Children) Act 2021. https://www.legislation.gov.uk/ukpga/2021/16/contents/enacted
  6. DHSC. Botulinum toxin and cosmetic fillers for under-18s: guidance for enforcement officers. https://www.gov.uk/government/publications/botulinum-toxin-and-cosmetic-fillers-for-under-18s-guidance-for-enforcement-officers/botulinum-toxin-and-cosmetic-fillers-for-under-18s-guidance-for-enforcement-officers
  7. ASA/CAP. Advertising rules for botulinum toxin. https://www.asa.org.uk/advice-and-resources/cap-bitesize/rules-for-advertising-botox.html
  8. GMC. Good practice in prescribing and managing medicines and devices. https://www.gmc-uk.org
  9. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992 Jan;18(1):17-21. https://pubmed.ncbi.nlm.nih.gov/1740562/
  10. Karagama Y. Abelchia: inability to belch/burp - a new disorder? Retrograde cricopharyngeal dysfunction (RCPD). Eur Arch Otorhinolaryngol. 2021 Dec;278(12):5087-5091. https://pubmed.ncbi.nlm.nih.gov/33893849/

Disclaimer: This guide is for general information only and does not constitute medical advice. It describes a prescription-only medicine and the law governing it, and is not an advertisement for any treatment. If you have questions about a procedure you are considering, discuss them with a qualified prescriber who has assessed you in person. For further information, visit drmunroe.com or contact clinic@drmunroe.com.

Free guide

the skincare 'brilliant basics' guide.

The routine Dr Munroe recommends to most patients, and what actually helps with pigmentation. Leave your email and the guide opens straight away.

Thank you. Your guide is ready.

Open the guide (PDF)
Ask Dr Munroe a question